This article was originally published in Start Up
When it came time to build a pipeline, airPharma's founders turned to a product they knew well for their lead compound:a drug formerly marketed as Pumactant, for neonatal respiratory distress. This compound is an inhalable synthetic pulmonary surfactant. The symptoms of asthma have been associated with surfactant dysfunction.
You may also be interested in...
Asthma represents one of the blockbuster markets in the pharmaceutical industry; sales of drugs from 10 companies amount to $14 billion each year. Yet despite the high-volume sales of asthma drugs, in 73% of patients the disease is poorly controlled. For pharmaceutical firms and start-ups, the complex, multifactorial disease offers tantalizing possibilities; it's an enormous, yet underserved market with many points of entry, mechanistically speaking.
Entrants now have an additional week to submit entries for the Global Generics & Biosimilars Awards 2022, which returns to Frankfurt this November.
A shift in investor sentiment in 2021 hit Everest hard when it was expanding the commercial team for cancer drug Trodelvy. Entering 2022, the sustained downturn in the capital market environment eventually changed the way the Chinese biotech considers launching drugs in the market.